A Randomized, Double-blind, Placebo Controlled Study of Vedolizumab for the Prevention of Post-operative Crohn's Disease Recurrence
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms Vedo Post-op
- 15 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 15 Aug 2017 Planned initiation date changed from 1 Sep 2016 to 1 Sep 2017.
- 19 Jul 2016 New trial record